

## CHANGING THE TRAJECTORY OF PARKINSON'S DISEASE

### INDUSTRY:

AI/ML drug discovery focused on neurology and oncology

### BUSINESS MODEL:

Identify unique therapeutic opportunities using Sinopia's AI/ML platform, perform proof-of-concept (pre)clinical studies, license/ partner with biotech/pharma

### LEAD PROGRAM:

Novel small molecule (SB-0110) for treatment of Parkinson's disease (PD) and levodopa-induced dyskinesia (LID)

### FUNDING TO-DATE:

**\$17M in non-dilutive funding** including \$5.3M from the NIH and The Michael J. Fox Foundation (MJFF) to complete IND-enabling studies

### DEVELOPMENT STAGE:

In IND-enabling studies to start Ph 1a/b by mid 2025

### FUNDING OPPORTUNITY:

Seeking \$30M Series A funding to complete Ph 1a/b clinical studies (including PD patients)

### TEAM:

Iman Famili, Ph.D., CEO  
Aarash Bordbar, Ph.D., CTO  
Tanya Simuni, M.D., Act. CMO

### SCIENTIFIC ADVISORY BOARD:

(world-class KOLs in Parkinson's disease and drug development)  
Kalpana Merchant, Ph.D.  
David Weiner, M.D.  
Tanya Simuni, M.D.

### CONTACT INFORMATION:

Iman Famili, CEO  
ifamili@sinopiabio.com

www.sinopiabio.com  
Located at JLABS San Diego

Sinopia Biosciences is leveraging an AI/machine learning platform to identify first-in-class therapeutics in neurology and oncology. Sinopia is studying diseases and compounds at an unprecedented biomolecular level, enabled by advances in data-driven technologies and data analytics using its drug discovery platform, LEADS® (LEarn And DiScover). LEADS® has successfully identified two therapeutic opportunities, including a first-in-class therapy for Parkinson's disease (PD) and levodopa-induced dyskinesia (LID).

### The Challenge:


PD is the fastest growing neurological disorder worldwide (7M patients globally). Levodopa (L-DOPA) is the first and still the best treatment for PD, however long-term use of L-DOPA results in motor fluctuations (loss of efficacy) and dyskinesia (side effect) in virtually all patients. **Dyskinesia and motor fluctuations are one of the largest unmet needs in PD outside a cure.**

### Replacing the Standard of Care in Parkinson's Disease:


Sinopia's therapeutic candidate (SB-0110) offers a number of key advantages:

- **First-in-class** small molecule (targeting PKA-Ril) with a **dual effect** to address both the symptoms of Parkinson's disease (PD) and levodopa-induced dyskinesia (LID), with potential for **cognitive benefits**.
- **Large and consistent pre-clinical efficacy** in highly translatable primate and rodent models of PD motor symptoms, in both acute and chronic treatments.
- **Strong patent position** (4 issued patents and composition of matter filings by Sinopia), with additional filings for other CNS indications.
- **Favorable safety profile** demonstrated in multi-year clinical trials for the parent compound under chronic usage with elderly patients.
- High value opportunity with potential to **replace the standard of care in Parkinson's disease**.

### LEADS® DRUG DISCOVERY PLATFORM



**STRONG ANTI-LID EFFECT IN PRIMATES.** SB-0107, parent compound; SB-0110, Sinopia's development candidate; Amantadine, the only approved LID drug with significant side effects.



### AI/ML Drug Discovery Platform with Multiple Product Opportunities:

|                              | \$17M<br>NIH & MJFF<br>funding | FUNDING | LEARN                               | DISCOVER                | DEVELOP                 |
|------------------------------|--------------------------------|---------|-------------------------------------|-------------------------|-------------------------|
|                              |                                |         | Identify Signatures<br>& Mechanisms | Target/Cpd<br>Discovery | In vivo<br>validation   |
| Parkinson's<br>disease / LID | NIH / MJFF                     |         |                                     |                         | Optimization            |
| Oral Mucositis               | NIH                            |         |                                     |                         | IND-enabling<br>studies |
| Oncology                     | NIH                            |         |                                     |                         |                         |

### High Value Investment Opportunity:

Sinopia is seeking **\$30M Series A** funding to complete Phase 1a/b studies (including with PD patients) in two years.